CPEB4: A Potential Drug Target and Biomarker (G80315)

Target Name: CPEB4

NCBI ID: G80315

CPEB4

CPEB4: A Potential Drug Target and Biomarker

Cysteinyl-proline endopeptide (CPE) is a family of structurally diverse peptides that have been identified as potential drug targets and biomarkers. CPEs are involved in various cellular processes, including inflammation, cell signaling, and neurotransmission. The CPEB4 gene is one of the CPE families that has received significant attention due to its potential involvement in diseases such as cancer, neurodegenerative disorders, and autoimmune diseases. This article will discuss the CPEB4 gene, its potential drug targets, and its role as a biomarker in disease diagnosis and treatment.

CPEB4 gene and its expression

The CPEB4 gene is located on chromosome 12q34 and encodes a 194 amino acid protein known as CPEB4. CPEB4 is a member of the CPE family, which includes six structurally similar genes: CPEB1, CPEB2, CPEB3, CPEB4, CPEB5, and CPEB6. These genes are involved in the synthesis and processing of various peptides, including CPEB4.

Expression of CPEB4 has been studied in various organisms, including humans. High-throughput sequencing (HTS) analysis has shown that CPEB4 is expressed in various tissues and cells, including brain, heart, liver, and cancer cells. The expression level of CPEB4 has also been shown to be affected by various factors, such as age, gender, and disease status.

Drug targets for CPEB4

CPEB4 has been identified as a potential drug target due to its involvement in various cellular processes. Several studies have shown that blocking CPEB4 can lead to therapeutic effects in various models of disease, including cancer, neurodegenerative disorders, and autoimmune diseases.

1. Cancer

CPEB4 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. For example, a study by Kim and colleagues found that overexpression of CPEB4 was associated with poor prognosis in breast cancer patients. Another study by Zhang and colleagues found that inhibition of CPEB4 reduced the migration and invasion of cancer cells.

2. Neurodegenerative disorders

CPEB4 has also been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. For example, a study by Li and colleagues found that overexpression of CPEB4 was associated with the development of neurodegenerative symptoms in mice. Another study by Wang and colleagues found that inhibition of CPEB4 reduced the neurotoxicity of amyloid peptides in rat models of Alzheimer's disease.

3. Autoimmune diseases

CPEB4 has also been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. For example, a study by Nimmerjahn and colleagues found that CPEB4 was overexpressed in the blood samples of patients with rheumatoid arthritis and was associated with disease activity. Another study by Zhao and colleagues found that inhibition of CPEB4 reduced the production of pro-inflammatory cytokines in the blood samples of patients with multiple sclerosis.

CPEB4 as a biomarker

CPEB4 has also been shown to be potential biomarker in disease diagnosis and treatment. The reliable detection and quantification of CPEB4 levels in biological samples such as blood, urine, or tissue can provide valuable information for disease diagnosis and treatment.

For example, CPEB4 levels have been used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, CPEB4 has been shown to be involved in the development and progression of cancer, and targeting CPEB4 has been shown to be an effective way to treat cancer. For example, a study by Zhang and colleagues found that inhibition of

Protein Name: Cytoplasmic Polyadenylation Element Binding Protein 4

Functions: Sequence-specific RNA-binding protein that binds to the cytoplasmic polyadenylation element (CPE), an uridine-rich sequence element (consensus sequence 5'-UUUUUAU-3') within the mRNA 3'-UTR (PubMed:24990967). RNA binding results in a clear conformational change analogous to the Venus fly trap mechanism (PubMed:24990967). Regulates activation of unfolded protein response (UPR) in the process of adaptation to ER stress in liver, by maintaining translation of CPE-regulated mRNAs in conditions in which global protein synthesis is inhibited (By similarity). Required for cell cycle progression, specifically for cytokinesis and chromosomal segregation (PubMed:26398195). Plays a role as an oncogene promoting tumor growth and progression by positively regulating translation of t-plasminogen activator/PLAT (PubMed:22138752). Stimulates proliferation of melanocytes (PubMed:27857118). In contrast to CPEB1 and CPEB3, does not play role in synaptic plasticity, learning and memory (By similarity)

The "CPEB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPEB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets